Navigation Links
New treatment combination proves safe for head and neck cancer patients
Date:5/30/2009

PITTSBURGH, May 30 Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, M.D., associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI). The results will be disclosed at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) on May 30 in Orlando, Fla.

"We found that adding gefinitib to standard chemotherapy was well-tolerated by patients who had already received chemotherapy or were frail," said Dr. Argiris. "We had hoped this study would improve the survival rate of patients, but while gefinitib did postpone spread of the disease, it did not increase survival rates. The finding that the addition of gefinitib to chemotherapy can delay the growth of head and neck cancer suggests a potential beneficial effect from combination therapy."

One group of 136 patients in the placebo-controlled study received docetaxel alone, a standard treatment for head and neck cancer. A second group of 134 patients received gefinitib in addition to docetaxel. This was the first phase III randomized trial to examine the addition of gefinitib to chemotherapy for patients with head and neck cancer. Gefinitib, which also is known by the trade name Iressa, is a targeted therapy against the epidermal growth factor receptor (EGFR) with fewer side effects than traditional chemotherapies. Patients were able to take the drug orally and tolerated it well.

Dr. Argiris plans to conduct further studies to identify the subsets of patients most likely to respond to the drug and to examine patients' quality of life while taking the combination therapy.

Head and neck cancers are a group of biologically similar cancers originating from the upper aerodigestive tract, including the lip, mouth, nasal cavity, paranasal sinuses, pharynx and larynx that affect more than 45,000 individuals in the U.S. each year. Head and neck cancers are strongly associated with environmental and lifestyle risk factors, including tobacco smoking, alcohol consumption and certain strains of the sexually transmitted human papilloma virus.


'/>"/>

Contact: Courtney McCrimmon
McCrimmonCP@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. Better treatment selection and improved therapies -- key to improving prognosis in acute HF
2. Individualized treatment for heart failure is rarely available outside hospital
3. Minimally invasive stroke treatment produces better patient outcomes than surgical operation
4. Researchers develop light-treatment device to improve sleep quality in the elderly
5. New Fast and Precise Treatment Planning System Among Varian Medical Systems Highlights at American Brachytherapy Society 2009 Meeting
6. Bausch & Lomb Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis (Pink Eye)
7. Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook
8. Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight
9. Window for Stroke Treatment Opens Wider
10. New treatment option for patients with chronic hepatitis C
11. Process for Planning Safe Pain Treatment Outlined in Presentation at FDA Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... MA San Antonio, TX (PRWEB) , ... March ... ... and ISO certified medical imaging core lab with extensive therapeutic experience and operational ... a multi-year phase II immuno-oncology clinical trial for the treatment of non-small cell ...
(Date:3/22/2017)... Chesapeake, VA (PRWEB) , ... March 22, 2017 ... ... offering asset protection assistance and financial consultations to families and business owners in ... raise support for the local American Cancer Society Relay For Life event. , ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... financial planning, and related services to communities across eastern Texas, is announcing a ... of providing meals to hungry children and adults. , Consistently a top-rated ...
(Date:3/22/2017)... ... March 22, 2017 , ... Schneider Insurance and Financial, a ... owners throughout the Yellowstone Valley region, is launching a charity event aimed at raising ... garden in all of Montana State, and is home to a broad variety of ...
(Date:3/22/2017)... ... March 22, 2017 , ... Chris Humphrey Insurance Agency, a North Carolina firm ... the coastal plains region, is initiating a charity event to raise support for five ... diagnosed with leukemia on a Friday evening in September 2014. At the time, Dillyn ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... Hologic, Inc. (Nasdaq: HOLX ) ... Cynosure, Inc., a leader in medical aesthetics systems and ... "We are pleased to complete our acquisition of Cynosure, ... and the entire Cynosure team to achieve even ... market," said Steve MacMillan , Hologic,s Chairman, President ...
(Date:3/22/2017)... FinancialBuzz.com News Commentary ... is strongly contributing to job creation. A recent report ... for the cannabis industry, projects that by 2020, the ... million jobs for American workers. The legal cannabis market ... is projected to grow at a compound annual growth ...
(Date:3/22/2017)... 22, 2017   Upsher-Smith Laboratories, Inc . (Upsher-Smith) today ... mg, 50 mg and 75 mg, the generic equivalent to ... The clomipramine hydrochloride capsules market had U.S. sales ... 2016, according to IMS Health. ... "Upsher-Smith has long been recognized within ...
Breaking Medicine Technology: